Edition:
United Kingdom

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

322.10DKK
23 Jan 2018
Change (% chg)

-- (--)
Prev Close
kr.322.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
397,164
52-wk High
kr.413.20
52-wk Low
kr.284.50

Latest Key Developments (Source: Significant Developments)

Lundbeck: Brintellix Approved In China
Monday, 4 Dec 2017 

Dec 4 (Reuters) - H Lundbeck A/S ::’S BRINTELLIX APPROVED IN CHINA.LAUNCH IS EXPECTED TO COMMENCE IN Q2 2018..  Full Article

Lundbeck Q3 EBIT above expectations at DKK 1.42‍​ bln
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - H LUNDBECK AS ::LUNDBECK INCREASED OPERATING PROFIT (EBIT) WITH 126% AND EPS BY 182% IN THE FIRST NINE MONTHS OF 2017 <<>>.‍NOW EXPECTS REVENUE TO REACH DKK 16.9-17.4 BILLION AND EBIT TO REACH DKK 4.3-4.6 BILLION FOR 2017​.‍REVENUE REACHED DKK 12,842 MILLION IN FIRST NINE MONTHS OF 2017​.‍PREVIOUSLY EXPECTED REVENUE OF DKK 16.7-17.5 BILLION AND EBIT OF DKK 4.1-4.5 BILLION​.Q3 REVENUE DKK 4.35‍​ BILLION (REUTERS POLL DKK 4.38 BILLION).Q3 EBIT DKK 1.42‍​ BILLION (REUTERS POLL DKK 1.19 BILLION).  Full Article

Otsuka Holdings unit and Lundbeck to initiate third Phase 3 trial to evaluate brexpiprazole in treatment of agitation in patients with dementia of Alzheimer's type
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says co's unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S will initiate a third clinical phase 3 study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type, in the first half of 2018.  Full Article

Lundbeck chairman says interim CEO will not become permanent CEO
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - LUNDBECK CHAIRMAN SAYS:INTERIM CEO GOTZSCHE WILL NOT BECOME PERMANENT CEO FOR LUNDBECK.CERTAIN NEXT CEO WILL BE EXTERNAL CANDIDATE.  Full Article

Lundbeck says Anders Gotzsche to be interim CEO from Nov 1
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Lundbeck - :CHANGES TO LUNDBECK'S EXECUTIVE MANAGEMENT .‍BOARD DECIDED THAT AS OF NOV 1 ANDERS GÖTZSCHE WILL TAKE OVER OPERATIONAL MANAGEMENT OF CO AS INTERIM CEO UNTIL NEW CEO IS IN PLACE​.  Full Article

Otsuka and Lundbeck announce initiation of two phase 3 trials of brexpiprazole in patients with bipolar I disorder
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:unit Otsuka Pharmaceutical Co., Ltd. and Lundbeck announce that patient enrollment has been initiated in two global Phase 3 clinical trials to evaluate brexpiprazole for the treatment of patients with manic episodes associated with bipolar I disorder.  Full Article

Lundbeck ‍CEO resigns to join Teva Pharmaceutical Industries
Monday, 11 Sep 2017 

Sept 11 (Reuters) - LUNDBECK :‍KÅRE SCHULTZ HAS RESIGNED FROM HIS POSITION AS PRESIDENT AND CEO​.‍STAFFAN SCHÜBERG HAS ALSO RESIGNED FROM HIS POSITION AS CHIEF COMMERCIAL OFFICER TO JOIN A PRIVATELY HELD COMPANY AS CEO​.‍PROCESS OF FINDING A REPLACEMENT FOR KÅRE SCHULTZ AND STAFFAN SCHÜBERG WILL COMMENCE IMMEDIATELY​.‍KÅRE SCHULTZ HAS RESIGNED FROM HIS POSITION AS PRESIDENT AND CEO TO JOIN TEVA PHARMACEUTICAL INDUSTRIES LTD. <<>> AS PRESIDENT AND CEO​.‍BOARD SEES NO REASON FOR CHANGES IN STRATEGIC DIRECTION OF COMPANY​.  Full Article

H Lundbeck Q3 EBIT DKK 589 million, beats expectations
Wednesday, 2 Nov 2016 

H Lundbeck A/S : Q3 revenue 3.95 billion Danish crowns ($587.5 million)(Reuters poll 3.71 billion crowns) . Q3 EBIT 589 million crowns (Reuters poll 449 million crowns) . Sees profit from operations (EBIT) to reach 2.1 billion-2.3 billion crowns for 2016 .Now expects 2016 revenue to reach 15.3 billion-15.7 billion crowns.  Full Article

Lundbeck says alzheimer's drug late stage study fails
Thursday, 22 Sep 2016 

H Lundbeck A/S : In first study, idalopirdine did not meet primary endpoint . Conclusions from first out of three phase 3 studies on idalopirdine in alzheimer's disease . Idalopirdine was safe and well tolerated .Two remaining studies, Starbeam and StarbrightII in phase 3 programme will continue as planned, data expected in first quarter of 2017.  Full Article

Lundbeck Q2 EBIT beats expectations; raises FY outlook
Wednesday, 24 Aug 2016 

H Lundbeck A/S : Q2 revenue 3.75 billion Danish crowns ($568.8 million) (Reuters poll 3.67 billion crowns) . Q2 EBIT 469 million crowns (Reuters poll 414 million crowns) . Now expects 2016 revenue of around 14.6 billion - 15.0 billion crowns compared to previously 14.2 billion - 14.6 billion crowns .2016 EBIT is expected to reach 1.5 billion - 1.7 billion crowns compared to 1.3 billion - 1.5 billion crowns.  Full Article

BRIEF-H Lundbeck Enters Research Partnership On Treatment Of Schizophrenia

* LUNDBECK ENTERS RESEARCH PARTNERSHIP ON NOVEL TREATMENT OF SCHIZOPHRENIA